Nevro’s product is now the only spinal cord stimulation system labeled to treat the condition, the company said.
The FDA approval came after the company conducted a 12-month study into its system’s treatment of back pain. The company said study participants saw improvements in pain relief, quality of life and a reduction in daily opioid use compared to conventional treatments.
